The FDA on 10 September gave Medivation and Astellas the go-ahead to market Xtandi (enzalutamide/MDV3100) as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC) not previously treated with chemotherapy – expanding the drug's use.
The companies initially won approval of Xtandi, an oral, once-daily androgen receptor inhibitor, in August 2012 as a treatment for...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

